Shire
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Shire sits in the top decile of US sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count).
Shire: 245 sponsored US clinical trials, 1 recruiting.
Shire sponsors 245 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 212 completed. 118 of these trials are in Phase 3-4 (later-stage) and 108 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 6 trials.
Top-decile sponsor footprint
Shire ranks in the top decile of sponsors by registered trial count (#133 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
212 of 242 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
245 total, page 2 of 5
A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
NCT02605837
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
NCT02604407
Natural History Study of Children With Metachromatic Leukodystrophy
NCT01963650
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
NCT02584959
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
NCT02455622
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
NCT02578030
A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
NCT05556629
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
NCT02466386
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT02466425
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
NCT02402166
Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094
NCT02412787
An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.
NCT02350816
Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)
NCT02386839
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
NCT02093663
A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
NCT02284516
A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations
NCT02204579
Short Term Observational Study in DEB Patients
NCT02178969
Taste Assessment Study of SHP429 in Healthy Adult Subjects
NCT02125292
Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)
NCT02095015
A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants
NCT02093923
Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment
NCT02055118
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema
NCT02052141
Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease
NCT02060526
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
NCT02045264
Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT02009163
Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
NCT01919801
Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects
NCT01989169
Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects
NCT01979185
A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
NCT01952080
The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects
NCT01905553
Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
NCT01898884
A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects
NCT01923207
A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)
NCT01905540
Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers
NCT01890785
FST-100 in the Treatment of Acute Viral Conjunctivitis
NCT01461954
AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184
NCT01824446
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access
NCT01806584
An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access
NCT01806545
Long-Term Safety Of PF-00547659 In Ulcerative Colitis
NCT01771809
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers
NCT01807000
Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers
NCT01786876
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
NCT01707667
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks
NCT01756157
Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
NCT01760993
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
NCT01760889
Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)
NCT01822184
FST-100 in the Treatment of Acute Adenoviral Conjunctivitis
NCT01470664
A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
NCT01743729
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT01718483
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
NCT01718509
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 56 |
| Phase 3 | 98 |
| Phase 4 | 20 |
What is open in the Shire pipeline
1 recruiting of 245 indexed (0% open); 212 completed (87%).
Phase mix: 118 late (III/IV) vs 108 early (I/II) (balanced across stages).
Top condition: Healthy (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Shire: open-pipeline peers nationwide
Peers matched on 245 registered trials and 0% open enrollment, not the therapeutic-area sidebar.
Shire sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 245 trials (± recruiting share)
- University of Cincinnati · 245 trials · 14% recruiting
- State University of New York at Buffalo · 243 trials · 21% recruiting
- Masonic Cancer Center, University of Minnesota · 249 trials · 14% recruiting
- University of Massachusetts, Worcester · 240 trials · 13% recruiting
Sponsors near 0% open enrollment (± trial volume)
- Gynecologic Oncology Group · 1% recruiting · 154 trials
- Mylan Pharmaceuticals · 1% recruiting · 146 trials
- Johnson & Johnson Vision Care · 1% recruiting · 142 trials
- 10xBio · 0% recruiting · 3 trials
Related
What to do with this Shire page
245 registered trials is a research-attention snapshot, not an endorsement of Shire or any single study.
- 1 of Shire's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Shire studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Shire pipeline card: 245 registered trials from official public datasets.Report a data error.